Takeda is Japan's largest pharma with a global rare disease and specialty franchise (Entyvio, Takhzyro, plasma-derived therapies). The post-Shire integration is largely complete, and deleveraging has progressed substantially. Patent expirations on Vyvanse and approaching Entyvio LOE create revenue cliff concerns. Pipeline replenishment via TAK-861 (narcolepsy), oncology assets, and BD activity is the recovery thesis. Yen weakness provides translation tailwind.
Thesis reviewed May 29, 2026
Takeda Pharmaceutical Company Limited is headquartered in Japan, which is currently showing moderate signals.
π―π΅Japan66NEUTRALView Japan risk detail βπPharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Ξ | Action |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 50 | +8% | β0% | NEUTRAL |
| LLY | Eli Lilly and Company | 50 | +24% | β0% | EARLY |
| TAK | Takeda Pharmaceutical Company Limited | 50 | +10% | β0% | NEUTRAL |
| REGN | Regeneron Pharmaceuticals Inc. | 50 | -16% | β0% | AVOID |
| SNY | Sanofi | 50 | +14% | β0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | β0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | β0% | EARLY |
Investors who hold TAK may also have indirect exposure through these country funds.
Takeda reports positive Phase 3 data for orexin agonist TAK-861
Takeda announces dividend hike on improved cash flow visibility
Estimates Β· Yahoo Finance Β· Not audited figures
[House Hearing, 119 Congress] [From the U.S. Government Publishing Office] CFTC REAUTHORIZATION: STAKEHOLDER PERSPECTIVES ======================================================================= HEARING BEFORE THE COMMITTEE ON AGRICULTURE HOUSE OF REPRESENTATIVES ONE HUNDRED NINETEENTH CONGRESS β¦